Investment analytics for health care venture firms
A thought partner to venture investors evaluating, structuring, managing, and exiting health care investments.
"Scoping an engagement — clarifying the end goal, determining what information is available, and constructing a game plan — is the hard part. Smooth, on-time, and in-budget execution only follows a well-scoped beginning."
Every Green Shoots engagement begins with a structured discovery process. Before any work begins, the right questions are asked: What decisions will this engagement support? What information is available? What assumptions are defensible? What are key sensitivities? Getting these right at the outset is crucial for ultimate success.
Investment Evaluation
Green Shoots partners with venture investors on investment decisions — evaluating new opportunities or exit offers, and stress-testing outcomes as market conditions evolve. Engagements focus on the value drivers that actually move the answer — commercial ramp, reimbursement dynamics, competitive positioning, and cost structure — and frequently involve complex licensing economics including royalty rate tiers, milestone payment triggers, sublicense fees, offsets for third-party obligations, and haircut provisions across multiple scenarios. Where commercially available data is insufficient to support key assumptions, Green Shoots commissions primary research through specialist firms — including KOL interviews with regulatory and reimbursement experts — grounding analysis in real market intelligence.
Transaction & Company Formation
Green Shoots provides hands-on transaction support for the formation of new companies from existing intellectual property — including academic and institutional spinouts. Engagements have included term sheet negotiation for IP out-licenses from academic medical centers, cap table structuring, founder share and option pool allocations, third-party technology evaluations, pro forma financial modeling, and investment committee presentation preparation. This capability is relevant to venture capital funds evaluating spinout opportunities, as well as technology transfer offices at universities and research institutions seeking an experienced financial and strategic partner to support company formation and early-stage capitalization.
Select Engagements
Case Study #1
rNPV Valuation Framework — Biotech Platform Company
A client needed a high-level valuation tool for an older portfolio company position it was considering selling. Its existing model was stale and the original owner had left the firm.
The core challenge was not the modeling itself — it was architecting a clean valuation
framework for a complicated drug asset portfolio at various stages of current and future
development with varied and complex license terms, while identifying the key variables that actually
impact value. Several conversations were held with the client to determine what information
was available to them, what level of granularity mattered, and when the final product was needed.
The model went through numerous iterations before landing on a structure that was
easy for an auditor to follow and capable of handling 100's of assets across time
cohorts and development stages — from Research Funding through Marketed. The final
on-time deliverable produced granular and portfolio-level NPV components with a dedicated
sensitivity analysis tab housing six key assumption inputs. The model was clear and
self-contained enough for the client to maintain it independently going forward.
Case Study #2
Single Drug Asset — Royalty & Milestone Trust Valuation
A client owned part of a royalty and milestone trust for a single commercial-stage drug asset and needed a detailed revenue build and deal terms DCF model to evaluate the position. Green Shoots built the first version at the time of initial FDA approval and commercial launch, and updated it annually over eight years as the drug moved through its commercial lifecycle — from launch to the approach of patent expiration.
The license economic terms were complex - royalty rate tiers and haircut triggers, commercial milestones, sublicense fees, and an offset for economics owed to a separate trust – but known and static. The revenue forecast was far more uncertain and dynamic.
Early in the engagement, Green Shoots commissioned primary market research with a specialist firm conducting KOL interviews to determine potential market demand and the competitive landscape. Each annual update involved reconciliation of actual revenue results, refreshing market research and script data, referencing analyst estimates and recalibrating assumptions and scenarios. Over time, this iterative process produced deep insight into the royalty stream's key value drivers and mechanics: competitive launches, label expansions, patent challenges, pricing pressure, manufacturing shortages, wholesaler inventory changes, refill rates, seasonality, and rebate accounting mechanics.
When a purchase offer arrived, the model was ready. Eight years of iterative refinement meant the analysis could move quickly and confidently, with assumptions grounded in the full commercial history of the asset.
Case Study #3
IP Out-License & Company Formation — Academic Medical Center Spinout
A venture capital fund engaged Green Shoots to provide transaction support in connection
with the formation of a new company built around AI-powered digital pathology technology
developed at a leading academic medical center. Working closely with the fund's investment
partner, Green Shoots played a central role across multiple workstreams in what was one of
the most complex engagements in the firm's history.
Green Shoots assisted in drafting the term sheet for the out-license of intellectual
property from the academic medical center into the newly formed company, supporting
negotiations across the founders, the institution, the fund, and their respective legal
counsel. Cap table structuring and financial modeling were completed concurrently, including founder share and stock option pool allocations.
To support the investment decision, Green Shoots engaged a third-party technology expert
to evaluate the diagnostic platform's clinical and commercial potential, and prepared pro
forma financial projections and an investment committee presentation for formal approval
by the fund's investment board.
Green Shoots Consulting, LLC provides analytical and strategic advisory services. Content on this site is for informational purposes only and does not constitute investment advice, a formal valuation opinion, or an offer to buy or sell any security. Green Shoots Consulting, LLC is not a registered investment adviser or broker-dealer. Full disclaimer →
Investment Evaluation